Leerink Partners cuts target for Boston Scientific stock to USD 55.00
Published on 10/13/2026 at 11:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- Leerink Partners cut its Boston Scientific price target from USD 60.00 to USD 55.00 on October 12, 2026.
- Second-quarter revenue reached USD 5.44 billion, up 7.50 percent year over year, while adjusted earnings per share was USD 0.86.
- Boston Scientific stock was EUR 39.70 at Lang & Schwarz on October 13, 2026 at 11:52 a.m. CEST; market capitalization was USD 65.2 billion as of October 12, 2026.
Boston Scientific (ISIN US1011371077) stock was at EUR 39.70 at Lang & Schwarz on October 13, 2026 at 11:52 a.m. CEST. On October 12, 2026, Leerink Partners cut its price target from USD 60.00 to USD 55.00 while maintaining a Buy rating, according to Markets Insider.
Target cut meets stronger quarterly revenue
Boston Scientific reported USD 5.44 billion of revenue in the second quarter of 2026, up 7.50 percent from USD 5.06 billion in the second quarter of 2025. Adjusted earnings per share reached USD 0.86, compared with a consensus estimate of USD 0.83, while adjusted operating margin was 28.40 percent.
The company also narrowed its full-year 2026 outlook to organic revenue growth of 5.00 percent to 6.00 percent and adjusted earnings per share of USD 3.28 to USD 3.32. The second-quarter earnings call transcript said the outlook reflected pressure in WATCHMAN and electrophysiology, while interventional cardiology and other businesses continued to support growth, according to Yahoo Finance.
Three dated signals for Boston Scientific
On July 29, 2026, Boston Scientific reported USD 5.44 billion in second-quarter revenue and adjusted earnings per share of USD 0.86, according to Yahoo Finance. On October 5, 2026, Bernstein lowered its price target from USD 60.00 to USD 54.00 while retaining an Outperform rating, as Investing.com reported. On October 12, 2026, Leerink Partners set the newer USD 55.00 target.
What does the target cut change?
The latest target remains USD 1.16 above the USD 53.84 level implied by a 2.00 percent premium to the companys current EUR quote only if currencies are converted, so that cross-currency comparison is not used here. The cleaner signal is the contrast between second-quarter revenue growth of 7.50 percent and the more cautious full-year organic growth outlook of 5.00 percent to 6.00 percent.
Boston Scientific stock stays below its yearly high
Boston Scientific had a market capitalization of USD 65.2 billion as of October 12, 2026. Its Nasdaq 52-week range was USD 41.39 to USD 105.65, placing the latest US quote near the lower end of that range while the Lang & Schwarz price provides the euro perspective for German investors.
The further course of trading is shown by the continuously updated real-time quote of Boston Scientific stock.
Boston Scientific stock facts
- Company: Boston Scientific Corporation
- ISIN: US1011371077
- WKN: 884113
- Ticker: BSX
- Primary exchange: NYSE
- Price Lang & Schwarz as of October 13, 2026, 11:52 a.m. CEST: EUR 39.70
- Market capitalization: USD 65.2 billion (as of October 12, 2026)
- 52-week range: USD 41.39-105.65
- Sector / Industry: Health Care / Medical Devices
- Index membership: S&P 500
Market context: Market report S&P 500.
